Multicenter, Parallel-group, Double-blind, Randomized, Active-controlled, Dose-ranging Study to Assess the Safety, Efficacy, and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors, in Subjects With Dyslipidemia
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Atorvastatin (Primary) ; Rocacetrapib (Primary) ; Rosuvastatin (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Chong Kun Dang
- 05 Nov 2018 Status changed from not yet recruiting to completed.
- 05 Dec 2016 New trial record